LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

LLY

1,061.02

+5.18%↑

JNJ

246.17

+1.51%↑

ABBV

228.89

+1.84%↑

NVS

165.48

+1.71%↑

MRK

123.5

+1.01%↑

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Open

1.23 -5.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.23

Max

1.27

Belangrijke statistieken
By Trading Economics
Werknemers	37

Dividenden
By Dow Jones
Volgende Winsten	30 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-20M 84M
Vorige openingsprijs	6.61
Vorige sluitingsprijs	1.23

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 feb 2026, 23:55 UTC

Marktinformatie

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Marktinformatie

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Marktinformatie

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Marktinformatie

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Marktinformatie

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Winsten

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Winsten

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Winsten

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Winsten

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Winsten

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Winsten

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Winsten

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Winsten

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Winsten

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Winsten

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Winsten

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Winsten

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Acquisities, Fusies, Overnames

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisities, Fusies, Overnames

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Winsten

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Winsten

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Marktinformatie

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisities, Fusies, Overnames

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.